Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis and Glenmark partner

Sanofi-aventis and Glenmark Pharmaceuticals have entered into a licensing agreement for the development of chronic pain treatments

Sanofi-aventis (S-A) and Glenmark Pharmaceuticals have entered into a licensing agreement for the development and commercialisation of new chronic pain treatments.

Indian drug company, Glenmark, will receive $20m initially, and additional payments of as much as $325m linked to development, regulatory and sales milestones. French drug maker, S-A, may also pay royalties on sales of products commercialised under the agreement.

S-A will have exclusive marketing rights in North America, the EU and Japan subject to Glenmark's right to co-promote the products in the US and five Eastern European countries. S-A will also have co-marketing rights in 10 other countries including Brazil, Russia and China. Glenmark will retain exclusive rights in India and other countries.

On the day the news was announced, Glenmark advanced 3.6 per cent to 279.45 rupees at the close of trading – the stock's biggest gain since March 29, 2010.

4th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics